Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Go back to Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease| (NASDAQ: MCRB) | Delayed: 6.60 -0.01 (0.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.61 | 52 Week High | $44.51 | |||
| Open | $6.68 | 52 Week Low | $8.05 | |||
| Day High | $7.05 | P/E | N/A | |||
| Day Low | $6.31 | EPS | $0.00 | |||
| Volume | 81,636 | |||||
